|
End-of-day quote
Taiwan S.E.
2026-11-13
|
5-day change | 1st Jan Change | ||
| 46.70 TWD | +2.08% |
|
+6.74% | -21.25% |
| Market Cap | 5.62B 171M 155M 143M 129M 243M 16.09B 252M 1.72B 681M 8.59B 640M 627M 27.28B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.73B 205M 185M 171M 155M 291M 19.28B 302M 2.06B 817M 10.3B 767M 751M 32.7B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
78.86% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | +2.08% | ||
| 1 week | +6.74% | ||
| Current month | +1.63% | ||
| 1 month | -1.89% | ||
| 3 months | -12.55% | ||
| 6 months | -11.72% | ||
| Current year | -21.25% |
| 1 week | 44.2 |  | 47.25 |
| 1 month | 40.5 | | 48.9 |
| Current year | 40.5 | | 62.5 |
| 1 year | 40.5 | | 67.4 |
| 3 years | 40.5 | | 121 |
| 5 years | 40.5 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 1995-12-31 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 2003-04-13 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CHM | Chairman | - | 1995-12-31 |
Che Jen Chuang
BRD | Director/Board Member | - | 2012-06-17 |
Hung Min Hsieh
BRD | Director/Board Member | - | 2006-08-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.08% | +6.74% | -28.04% | -44.14% | 171M | |
| +1.26% | +6.61% | +41.12% | +135.59% | 1,286B | |
| +0.79% | +3.45% | +46.35% | +93.56% | 688B | |
| +0.20% | +1.28% | +27.01% | +112.80% | 521B | |
| -0.44% | +3.69% | +39.60% | +69.51% | 386B | |
| +0.55% | +0.70% | +59.00% | +44.20% | 364B | |
| -0.12% | +0.74% | +26.78% | +58.43% | 302B | |
| +0.37% | +0.37% | +3.62% | +36.44% | 287B | |
| -0.30% | +1.14% | +38.59% | +74.61% | 252B | |
| +0.08% | +0.71% | +34.25% | +124.32% | 208B | |
| Average | +0.45% | +2.32% | +28.83% | +70.53% | 429B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.63% | +96.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 144M 130M 120M 109M 205M 13.55B 212M 1.45B 574M 7.24B 539M 528M 22.98B | 4.85B 147M 134M 124M 111M 210M 13.9B 217M 1.48B 588M 7.42B 553M 541M 23.57B |
| Net income | 157M 4.78M 4.33M 4M 3.61M 6.81M 451M 7.05M 48.11M 19.08M 241M 17.93M 17.55M 764M | 441M 13.4M 12.14M 11.23M 10.14M 19.1M 1.26B 19.77M 135M 53.51M 675M 50.29M 49.23M 2.14B |
| Net Debt | 1.2B 36.34M 32.93M 30.46M 27.48M 51.79M 3.43B 53.61M 366M 145M 1.83B 136M 133M 5.81B | 1.12B 33.89M 30.71M 28.41M 25.63M 48.3M 3.2B 50M 341M 135M 1.71B 127M 124M 5.42B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-13 | NT$46.70 | +2.08% | 591,951 |
| 26-11-12 | NT$45.75 | +0.77% | 571,231 |
| 26-11-11 | NT$45.40 | +0.55% | 283,524 |
| 26-11-10 | NT$45.15 | +1.01% | 512,147 |
| 26-11-09 | NT$44.70 | +2.17% | 477,342 |
- Stock Market
- Stocks
- 4746 Stock
Select your edition
All financial news and data tailored to specific country editions
